Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-06T04:10:25.694Z Has data issue: false hasContentIssue false
  • English
  • Français

APP23 Mice as a Model of Alzheimer's Disease: An Example of a Transgenic Approach to Modeling a CNS Disorder

Published online by Cambridge University Press:  07 November 2014

Debby Van Dam ,
Ellen Vloeberghs ,
Dorothee Abramowski ,
Matthias Staufenbiel  and
Peter Paul De Deyn
Get access Rights & Permissions [Opens in a new window]

Abstract

Animal models are considered essential in research ensuing elucidation of human disease processes and subsequently, testing of potential therapeutic strategies. This is especially true for neurodegenerative disorders, in which the first steps in pathogenesis are often not accessible in human patients. Alzheimer's disease is vastly becoming a major medical and socioeconomic problem in our aging society. Valid animal models for this uniquely human condition should exhibit histopathological, biochemical, cognitive, and behavioral alterations observed in Alzheimer's disease patients. Major progress has been made since the understanding of the genetic basis of Alzheimer's disease and the development and improvement of transgenic mouse models. All present Alzheimer's disease models developed are partial but nevertheless essential in further unraveling the nature and spatial and temporal development of the complex molecular pathology underlying this condition. One of the more recent transgenic attempts to mode Alzheimer's disease is the APP23 transgenic mouse. This article describes the development and assessment of this human amyloid precursor protein overexpression model. We summarize histopathological and biochemical, cognitive and behavioral observations made in heterozygous APP23 mice, thereby emphasizing the model's contribution to clarification of neurodegenerative disease mechanisms. In addition, the first therapeutic interventions in the APP23 model are included.

Type
Review Articles
Information
CNS Spectrums , Volume 10 , Issue 3 , March 2005 , pp. 207 - 222
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Selkoe, DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81:741–766.Google Scholar
2. Hardy, J, Selkoe, DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356.Google Scholar
3. Schellenberg, GD. Genetic dissection of Alzheimer disease, a heterogeneous disorder. Proc Natl Acad Sci USA. 1995;92:8552–8559.Google Scholar
4. Cruts, M, Van Broeckhoven, C. Molecular genetics of Alzheimer's disease. Ann Med. 1998;30:560–565.Google Scholar
5. Campion, D, Dumanchin, C, Hannequin, D, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet. 1999;65:664–670.CrossRefGoogle ScholarPubMed
6. Evans, DA, Beckett, LA, Field, TS, et al. Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons. JAMA. 1997;277:822–824.Google Scholar
7. Slooter, AJ, Cruts, M, Kalmijn, S, et al. Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. Arch Neurol. 1998;55:964–968.Google Scholar
8. Hofman, A, Rocca, WA, Brayne, C, et al. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Eurodem Prevalence Research Group. Int J Epidemiol. 1991;20:736–748.Google Scholar
9. van Zutphen, LFM, De Deyn, PP. Animal use in experimental neuropathology: provisions for animal welfare and ethics. Neurosci Res Commun. 2000;26:149–160.Google Scholar
10. De Deyn, PP, D'Hooge, R, van Zutphen, LFM. Animal models of human disorders - general aspects. Neurosci Res Commun. 2000;26:141–148.3.0.CO;2-V>CrossRefGoogle Scholar
11. Braak, H, Braak, E, Strothjohann, M. Abnormally phosphorylated tau protein related to the formation of neurofibrillary tangles and neuropil threads in the cerebral cortex of sheep and goat. Neurosci Lett. 1994;171:1–4.Google Scholar
12. Nelson, PT, Greenberg, SG, Saper, CB. Neurofibrillary tangles in the cerebral cortex of sheep. Neurosci Lett. 1994;170:187–190.Google Scholar
13. Cole, GM, Frautschy, SA. Animal models of Alzheimer's disease. Alz Dis Rev. 1997;2:33–41.Google Scholar
14. Janus, C, Westaway, D. Transgenic mouse models of Alzheimer's disease. Physiol Behav. 2001;73:873–886.Google Scholar
15. Whitehouse, PJ, Price, DL, Clark, AW, et al. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981;10:122–126.Google Scholar
16. Coyle, JT, Price, DL, DeLong, MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 1983;219:1184–1190.Google Scholar
17. Spangler, EL, Rigby, P, Ingram, DK. Scopolamine impairs learning performance of rats in a 14-unit T-maze. Pharmacol Biochem Behav. 1986;25:673–679.Google Scholar
18. Pepeu, G, Casamenti, F, Pedata, F, Cosi, C, Pepeu, IM. Are the neurochemical and behavioral changes induced by lesions of the nucleus basalis in the rat a model of Alzheimer's disease? Prog Neuropsychopharmacol Biol Psychiatry. 1986;10:541–551.Google Scholar
19. Santucci, AC, Haroutunian, V, Davis, KL. Pharmacological alleviation of combined cholinergic/noradrenergic lesion-induced memory deficits in rats. Clin Neuropharmacol. 1991;14(suppl 1):S1–S8.Google Scholar
20. Muir, JL, Page, KJ, Sirinathsinghji, DJ, Robbins, TW, Everitt, BJ. Excitotoxic lesion of basal forebrain cholinergic neurons: effects on learning, memory and attention. Behav Brain Res. 1993;57:123–131.Google Scholar
21. Decker, MW, Majchrzak, MJ, Anderson, DJ. Effects of nicotine on spatial memory deficits in rats with septal lesions. Brain Res. 1992;572:281–285.Google Scholar
22. Miwa, C, Ueki, A. Effects of entorhinal cortex lesions on learning behavior and on hippocampus in the rat. Psychiatry Clin Neurosci. 1996;50:223–230.Google Scholar
23. Eijkenboom, M, Van Der Staay, FJ. Spatial learning deficits in rats after injection of vincristine into the dorsal hippocampus. Neuroscience. 1999;91:1299–1313.Google Scholar
24. Games, D, Adams, D, Alessandrini, R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 1995;373:523–527.Google Scholar
25. Hsiao, K, Chapman, P, Nilsen, S, et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 1996;274:99–102.Google Scholar
26. Janus, C, Pearson, J, McLaurin, J, et al. A β peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979–982.Google Scholar
27. Sturchler-Pierrat, C, Abramowski, D, Duke, M, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA. 1997;94:13287–13292.Google Scholar
28. Sturchler-Pierrat, C, Staufenbiel, M. Pathogenic mechanisms of Alzheimer's disease analyzed in the APP23 transgenic mouse model Ann N Y Acad Sci. 2000;920:134–139.Google Scholar
29. Kuo, YM, Kokjohn, TA, Beach, TG, et al. Comparative analysis of amyloid-β chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem. 2001;276:12991–12998.CrossRefGoogle ScholarPubMed
30. Vinters, HV. Cerebral amyloid angiopathy. A critical review. Stroke. 1987;18:311–324.Google Scholar
31. Calhoun, ME, Burgermeister, P, Phinney, AL, et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci USA. 1999;96:14088–14093.Google Scholar
32. Winkler, DT, Bondolfi, L, Herzig, MC, et al. Spontaneous hemorrhagic stroke in a mouse model of cerebral amyloid angiopathy. J Neurosci. 2001;21:1619–1627.CrossRefGoogle Scholar
33. Winkler, DT, Biedermann, L, Tolnay, M, et al. Thrombolysis induces cerebral hemorrhage in a mouse model of cerebral amyloid angiopathy. Ann Neurol. 2002;51:790–793.Google Scholar
34. Stalder, M, Phinney, A, Probst, A, Sommer, B, Staufenbiel, M, Jucker, M. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol. 1999;154:1673–1684.Google Scholar
35. Bornemann, KD, Wiederhold, KH, Pauli, C, et al. Aβ-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol. 2001;158:63–73.Google Scholar
36. Stalder, M, Deller, T, Staufenbiel, M, et al. 3D-Reconstruction of microglia and amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol Aging. 2001;22:427–434.CrossRefGoogle ScholarPubMed
37. Burbach, GJ, Hellweg, R, Haas, CA, et al. Induction of brain-derived neurotrophic factor in plaque-associated glial cells of aged APP23 transgenic mice. J Neurosci. 2004;24:2421–2430.Google Scholar
38. Burbach, GJ, Dehn, D, Del Turco, D, Staufenbiel, M, Deller, T. Laser microdissection reveals regional and cellular differences in GFAP mRNA upregulation following brain injury, axonal denervation, and amyloid plaque deposition. Glia. 2004;48:76–84.Google Scholar
39. Pezet, S, Malcangio, M. Brain-derived neurotrophic factor as a drug target for CNS disorders. Expert Opin Ther Targets. 2004;8:391–399.Google Scholar
40. Gartner, U, Bruckner, MK, Krug, S, Schmetsdorf, S, Staufenbiel, M, Arendt, T. Amyloid deposition in APP23 mice is associated with the expression of cyclins in astrocytes but not in neurons. Acta Neuropathol (Berl). 2003;106:535–544.Google Scholar
41. Phinney, AL, Deller, T, Stalder, M, et al. Cerebral amyloid induces aberrant axonal sprouting and ectopic terminal formation in amyloid precursor protein transgenic mice. J Neurosci. 1999;19:8552–8559.Google Scholar
42. West, MJ, Coleman, PD, Hood, DG, et al. Differences in the pattern of hippocampal neuron loss in normal aging and Alzheimer's disease. Lancet. 1994;344:769–772.Google Scholar
43. Regeur, L, Jensen, GB, Pakkenberg, H, et al. No global neurocortical nerve cell loss in brains from patients with senile dementia of Alzheimer's type. Neurobiol Aging. 1994;15:347–352.Google Scholar
44. Calhoun, ME, Wiederhold, KH, Abramowski, D, et al. Neuron loss in APP transgenic mice. Nature. 1998;395:755–756.Google Scholar
45. Bondolfi, L, Calhoun, M, Ermini, F, et al. Amyloid-associated neuron loss and glio-genesis in the neocortex of amyloid precursor protein transgenic mice. J Neurosci. 2002;22:515–522.Google Scholar
46. Mueggler, T, Sturchler-Pierrat, C, Baumann, D, et al. Compromised hemodynamic response in amyloid precursor protein transgenic mice. J Neurosci. 2002;22:7218–7224.CrossRefGoogle ScholarPubMed
47. Mueggler, T, Baumann, D, Rausch, M, et al. Age-dependent impairment of somatosensory response in the amyloid precursor protein 23 transgenic mouse model of Alzheimer's disease. J Neurosci. 2003;23:8231–8236.Google Scholar
48. Mueggler, T, Meyer-Luehmann, M, Rausch, M, et al. Restricted diffusion in the brain of transgenic mice with cerebral amyloidosis. Eur J Neurosci. 2004;20:811–817.Google Scholar
49. Beckmann, N, Schuler, A, Mueggler, T, et al. Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer's disease. J Neurosci. 2003;23:8453–8459.Google Scholar
50. Krucker, T, Schuler, A, Meyer, EP, et al. Magnetic resonance angiography and vascular corrosion casting as tools in biomedical research: application to transgenic mice modeling Alzheimer's disease. Neurol Res. 2004;26:507–516.Google Scholar
51. Okamura, N, Suemoto, T, Shiomitsu, T, et al. A novel imaging probe for in vivo detection of neuritic and diffuse amyloid plaques in the brain. J Mol Neurosci. 2004;24:247–255.Google Scholar
52. Okamura, N, Suemoto, T, Shimadzu, H, et al. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain. J Neurosci. 2004;24:2535–2541.Google Scholar
53. Suemoto, T, Okamura, N, Shiomitsu, T, et al. In vivo labeling of amyloid with BF-108. Neurosci Res. 2004;48:65–74.Google Scholar
54. Boncristiano, S, Calhoun, ME, Kelly, PH, et al. Cholinergic changes in the APP23 transgenic mouse model of cerebral amyloidosis. J Neurosci. 2002;22:3234–3243.Google Scholar
55. Van Dam, D, Marescau, B, Engelborghs, S, et al. Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models. Neurochem Int. 2005 Jan 17 [Epub ahead of print].Google Scholar
56. Diez, M, Danner, S, Frey, P, et al. Neuropeptide alterations in the hippocampal formation and cortex of transgenic mice overexpressing beta-amyloid precursor protein (APP) with the Swedish double mutation (APP23). Neurobiol Dis. 2003;14:579–594.Google Scholar
57. D'Hooge, R, De Deyn, PP. Applications of the Morris water maze in the study of learning and memory. Brain Res Rev. 2001;36:60–90.Google Scholar
58. Lalonde, R, Dumont, M, Staufenbiel, M, et al. Spatial learning, exploration, anxiety, and motor coordination in female APP23 transgenic mice with the Swedish mutation. Brain Res. 2002;956:36–44.Google Scholar
59. Van Dam, D, D'Hooge, R, Staufenbiel, M, et al. Age-dependent cognitive decline in the APP23 model precedes amyloid deposition. Eur J Neurosci. 2003;17:388–396.Google Scholar
60. Kelly, PH, Bondolfi, L, Hunziker, D, et al. Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol Aging. 2003;24:365–378.Google Scholar
61. Dumont, M, Strazielle, C, Staufenbiel, M, et al. Spatial learning and exploration of environmental stimuli in 24-month-old female APP23 transgenic mice with the Swedish mutation. Brain Res. 2004;1024;113–121.Google Scholar
62. Parvathy, S, Davies, P, Haroutunian, V, et al. Correlation between Abetax-40-, Abetax-42-, and Abetax-43-containing amyloid plaques and cognitive decline. Arch Neurol. 2001;58:2025–2032.CrossRefGoogle ScholarPubMed
63. Moran, PM, Higgins, LS, Cordell, B, et al. Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein. Proc Natl Acad Sci USA. 1995;92:5341–5345.Google Scholar
64. Chishti, MA, Yang, DS, Janus, C, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem. 2001;276:21562–21570.Google Scholar
65. Gordon, MN, King, DL, Diamond, DM, et al. Correlation between cognitive deficits and Abeta deposits in transgenic APP+PSI mice. Neurobiol Aging. 2001;22:377–385.Google Scholar
66. Hsiao, KK, Borchelt, DR, Olson, K, et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron. 1995;15:1203–1218.Google Scholar
67. D'Hooge, R, Nagels, G, Westland, CE, et al. Spatial learning deficit in mice expressing human 751-amino acid β-amyloid precursor protein. Neuroreport. 1996;7:2807–2811.Google Scholar
68. Kumar-Singh, S, Dewachter, I, Moechars, D, et al. Behavioral disturbances without amyloid deposits in mice overexpressing human amyloid precursor protein with Flemish (A692G) or Dutch (E693Q) mutation. Neurobiol Dis. 2000;7:9–22.Google Scholar
69. McLean, CA, Cherny, RA, Fraser, FW, et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 1999;46:860–866.Google Scholar
70. Kuo, YM, Beach, TG, Sue, LI et al. The evolution of A beta peptide burden in the APP23 transgenic mice: implications for Aβ deposition in Alzheimer disease. Mol Med. 2001;7:609–618.Google Scholar
71. Crawley, JN, Paylor, R. A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm Behav. 1997;31:197–211.Google Scholar
72. Tulving, E. Multiple memory Systems and consciousness. Hum Neurobiol. 1987;6:67–80.Google Scholar
73. Shinosaki, K, Nishikawa, T, Takeda, M. Neurobiological basis of behavioral and psychological symptoms in dementia of the Alzheimer type. Psychiatry Clin Neurosci. 2000;54:611–620.Google Scholar
74. Page, KJ, Everitt, BJ, Robbins, TW, et al. Dissociable effects on spatial maze and passive avoidance acquisition and retention following AMPA- and ibotenic acid-induced excitotoxic lesions of the basal forebrain in rats: differential dependence on cholinergic neuronal loss. Neuroscience. 1991;43:457–472.Google Scholar
75. Riekkinen, P Jr, Kuitunen, J, Riekkinen, M. Effects of scopolamine infusions into the anterior and posterior cingulate on passive avoidance and water maze navigation. Brain Res. 1995;685:46–54.Google Scholar
76. Deacon, RM, Bannerman, DM, Kirby, BP, et al. Effects of cytotoxic hippocampal lesions in mice on a cognitive test battery. Behav Brain Res. 2002;133:57–68.Google Scholar
77. Reisberg, B, Borenstein, J, Salob, SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatments. J Clin Psychiatry. 1987;48(suppl):9–15.Google Scholar
78. De Deyn, PP, Rabheru, K, Rasmussen, A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946–955.Google Scholar
79. De Deyn, PP, Wirshing, WC. Scales to assess efficacy and safety of pharmacological agents in the treatment of behavioral and psychological symptoms of dementia. J Clin Psychiatry. 2001;62(suppl 21):19–22.Google Scholar
80. Witting, W, Kwa, IH, Eikelenboom, P, et al. Alterations in the circadian rest-activity rhythm in aging and Alzheimer's disease. Biol Psychiatry. 1990;27:563–572.Google Scholar
81. Vloeberghs, E, Van Dam, D, Engelborghs, S, et al. Altered circadian locomotor activity in APP23 mice: a model for BPSD disturbances. Eur J Neurosci. 2004;20:2757–2766.Google Scholar
82. Meyer-Luehmann, M, Stalder, M, Herzig, MC, et al. Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci. 2003;6:370–377.CrossRefGoogle ScholarPubMed
83. Refolo, LM, Pappolla, MA, Malester, B, et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7:321–331.Google Scholar
84. Jick, H, Zornberg, GL, Jick, SS, et al. Statins and the risk of dementia. Lancet. 2000;365:1627–1631.Google Scholar
85. Lütjohann, D, Papassotiropoulos, A, Björkhem, I, et al. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res. 2000;41:195–198.Google Scholar
86. Papassotiropoulos, A, Lütjohann, D, Bagli, M, et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res. 2002;36:27–32.Google Scholar
87. Lütjohann, D, Brzezinka, A, Barth, E, et al. Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. J Lipid Res. 2002;43:1078–1085.Google Scholar
88. Förstermann, U, Gath, I, Schwarz, P, et al. Isoforms of nitric oxide synthase. Properties, cellular distribution and expressional control. Biochem Pharmacol. 1995;50:1321–1332.Google Scholar
89. Luth, HJ, Holzer, M, Gartner, U, et al. Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction hy amyloid pathology. Brain Res. 2001;913:57–67.Google Scholar
90. Beal, MF. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci. 2000;23:298–304.Google Scholar
91. Buchner, M, Huber, R, Sturchler-Pierrat, C, et al. Impaired hypoxic tolerance and altered protein binding of NADH in presymptomatic APP23 transgenic mice. Neuroscience. 2002;114:285–289.Google Scholar
92. Feig, S, Lipton, P. N-methyl-D-aspartate receptor activation and Ca2+ account for poor pyramidal cell structure in hippocampal slices. J Neurochem. 1990;55:473–483.CrossRefGoogle ScholarPubMed
93. Bliss, TV, Collingridge, GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361:31–39.Google Scholar
94. Chapman, PF, White, GL, Jones, MW, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci. 1999;2:271–276.Google Scholar
95. Hsia, AY, Masliah, E, McConlogue, L, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA. 1999;96:3228–3233.Google Scholar
96. Larson, J, Lynch, G, Games, D, et al. Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain Res. 1999;840:23–35.Google Scholar
97. Moechars, D, Dewachter, I, Lorent, K, et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem. 1999;274:6483–6492.Google Scholar
98. Fitzjohn, SM, Morton, RA, Kuenzi, F, et al. Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J Neurosci. 2001;21:4691–4698.Google Scholar
99. Roder, S, Danober, L, Pozza, MF, et al. Electrophysiological studies on the hippocampus and prefrontal cortex assessing the effects of amyloidosis in amyloid precursor protein 23 transgenic mice. Neuroscience. 2003;120:705–720.Google Scholar
100. Van Dam, D, Abramowski, D, Staufenbiel, M et al. Symptomatic effects of Donepezil, Rivastigmine, Galantamine and Memantine on cognitive deficits in the APP23 model. Psychopharmacology. 2005 Jan 15 [Epub ahead of print].Google Scholar
101. Pfeifer, M, Boncristiano, S, Bondolfi, L, et al. Cerebral hemorrhage after passive anti-Aβ immunotherapy. Science. 2002;298:1379.Google Scholar
102. Koldamova, RP, Lefterov, IM, Staufenbiel, M, et al. The LXR ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem. 2005;280:4079–4088.Google Scholar
103. Bayer, TA, Schafer, S, Simons, A, et al. Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Natl Acad Sci USA. 2003;100:14187–14192.Google Scholar
104. Schenk, D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci. 2002;3:824–828.Google Scholar
105. Gelinas, DS, DaSilva, K, Fenili, D, St George-Hyslop, P, McLaurin, J. Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci USA. 2004;101(suppl 2):14657–14662.Google Scholar
106. Marlow, L, Cain, M, Pappolla, MA, et al. Beta-secretase processing of the Alzheimer's amyloid protein precursor (APP). J Mol Neurosci. 2003;20:233–239.Google Scholar
107. Koldamova, RP, Lefterov, IM, Ikonomovic, MD, et al. 22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. J Biol Chem. 2003;278:13244–13256.Google Scholar
108. Brown, J 3rd, Theisler, C, Silberman, S, et al. Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem. 2004;279:34674–34681.Google Scholar
109. Sun, Y, Yao, J, Kim, TW, et al. Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. J Biol Chem. 2003;278:27688–27694.Google Scholar
110. Hesse, L, Beher, D, Masters, CL, et al. The beta A4 amyloid precursor protein binding to copper. FEBS Lett. 1994;349:109–116.Google Scholar
111. Atwood, CS, Scarpa, RC, Huang, X, et al. Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid betal-42. J Neurochem. 2000;75:1219–1233.Google Scholar
112. Borchardt, T, Schmidt, C, Camarkis, J, et al. Differential effects of zinc on amyloid precursor protein (APP) processing in copper-resistant variants of cultured Chinese hamster ovary cells. Cell Mol Biol. 2000;46:785–795.Google Scholar
113. Maynard, CJ, Cappai, R, Volitakis, I, et al. Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem. 2002;277:44670–44676.Google Scholar
114. Phinney, AL, Drisaldi, B, Schmidt, SD, et al. In vivo reduction of amyloid-beta by a mutant copper transporter. Proc Natl Acad Sci USA. 2003;100:14193–14198.Google Scholar
115. Leber, P. Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord. 1996;10(suppl 1):31–35.Google Scholar
116. Bodick, N, Forette, F, Hadler, D, et al. Protocols to demonstrate slowing of Alzheimer disease progression. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. The Disease Progression Sub-Group. Alzheimer Dis Assoc Disord. 1997;3(suppl 3):50–53.Google Scholar
117. Kittner, B, De Deyn, PP, Erkinjuntti, T. Investigating the natural course and treatment of vascular dementia and Alzheimer's disease. Parallel study populations in two randomized, placebo-controlled trials. Ann N Y Acad Sci. 2000;903:535–541.Google Scholar
118. Dewachter, I, van Dorpe, J, Spittaels, K, et al. Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice. Exp Gerontol. 2000;35:831–841.Google Scholar
119. Masliah, E, Sisk, A, Mallory, M, Games, D. Neurofibrillary pathology in transgenic mice overexpressing V717F β-amyloid precursor protein. J Neuropathol Exp Neurol. 2001;60:357–368.Google Scholar
120. Götz, J. Tau and transgenic animal models. Brain Res Brain Res Rev. 2001;35(3):266–286.Google Scholar
121. Götz, J, Chen, F, van Dorpe, J, et al. Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Aβ 42 fibrils. Science. 2001;293:1491–1495.Google Scholar
122. Lewis, J, McGowan, E, Rockwood, J, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402–405.Google Scholar
123. Crawley, JN, Belknap, JK, Collins, A, et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl). 1997;132:107–124.Google Scholar